Why Moderna Shares Are Rising

Moderna Inc MRNA shares are trading higher after the company reported results from a study in children 6-11 years of age and announced the primary immunogenicity endpoints were met.

According to the press release:

  • Results are the first from a pivotal study in children aged six years to under 12 years
  • Two 50 μg doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers; primary immunogenicity endpoints were met
  • Moderna plans to submit results to the U.S. FDA, EMA and regulatory agencies around the world soon

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. 

Moderna has a 52-week high of $497.49 and a 52-week low of $65.49.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!